https://rijournals.com/public-health-and-pharmacy/

RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2): 45-48, 2024

RIJPP Publications

ISSN ONLINE: 1115-8689

ISSN PRINT 1597-8559

https://doi.org/10.59298/RIJPP/2024/3234548

The role of Genetics in Cardiovascular Disease

Katu Amina H.

School of Natural and Applied Sciences Kampala International Uganda

ABSTRACT

Cardiovascular disease (CVD) is a leading cause of mortality worldwide, involving complex interactions between genetic and environmental factors. This paper explores the genetic components that contribute to CVD, particularly focusing on heritability, gene-environment interactions, and the role of genetic testing in predicting and managing cardiovascular risk. Although significant advancements have been made in identifying genetic markers linked to CVD, translating these findings into clinical practice remains challenging. Current research emphasizes the importance of large-scale studies, including diverse populations, to fully understand the genetic basis of CVD and improve personalized therapeutic strategies.

Keywords: Cardiovascular disease, genetics, atherosclerosis, heritability, gene-environment interaction.

INTRODUCTION

Cardiovascular disease (CVD) is a general term used to describe extensive pathology related to vascular disease. This includes progressive atherosclerosis with its sequelae and the phenotype of myocardial infarction, stroke, peripheral vascular disease (PVD), and a variety of 'silent' processes that are also the result of underlying atherosclerosis. They are responsible for the largest number of deaths in the United States and for an even larger number of disabilities and loss of normal lifestyle. The action of recognizing those at risk of cardiovascular disease, and the treatment and prevention efforts designed to slow the disease progression, if not eliminate it from the world, takes up a significant number of dollars in health care investment. Efforts at early recognition, efforts to slow progression, or attempts to manipulate the process of atherosclerosis itself all use the measure of atherosclerotic quantitation, with traditional markers at times being supplemented with more sophisticated imaging techniques. These have resulted in a growing number of tests predictive of cardiovascular disease risk that are available and evolving with rapidly changing technology. These tests are among the most beneficial and financially rewarding areas of expansion for clinical diagnostic laboratories [1, 2].

OVERVIEW OF CARDIOVASCULAR DISEASE

Cardiovascular disease (CVD) is a general term that refers to diseases of the heart and blood vessels. The most common forms of CVD are coronary heart disease, which occurs when the blood supply to the heart becomes blocked or restricted, causing chest pain and heart attack; and stroke, which occurs when the blood supply to part of the brain becomes blocked, causing brain cells to die, resulting in damage to that part of the brain [3, 4]. Each year, 1.6 million people in the UK suffer from a heart attack or stroke, which is responsible for one in five men and one in six women deaths. CVD also causes disability, with a high percentage of older adults having high blood pressure, both diagnosed and undiagnosed. This increases the risk of stroke or heart attack, as well as other complications. Hospitalizations and deaths associated with high blood pressure are on the rise. In addition, 2.6 million people in the UK live with diabetes, with 850,000 suffering from undiagnosed diabetes. Diabetes increases the risk of CVD due to high cholesterol and triglyceride levels, leading to artery blockage. After 40 years old, individuals with diabetes have up to four times the risk of CVD compared to those without [5, 6].

GENETIC FACTORS IN CARDIOVASCULAR DISEASE

There is a strong family history of premature cardiovascular disease in 50% of men and 30% of women who suffer myocardial infarction. Furthermore, if no family history of cardiovascular disease exists, men have twice the risk of women in developing cardiovascular disease at a given age. The cardiovascular risk factors do not account for this enhanced risk because positive and negative risk factors do not cluster differently in this group of patients. These data suggest that genetic factors may play an important role in the risk of cardiovascular disease. Studies on genetic factors for cardiovascular disease aim to find genes involved in disease development. The research with the greatest success has been linkage studies, the candidate gene search, and the analysis of gene-environment interactions. These studies have produced important knowledge about etiology, but the practical clinical consequences of this knowledge are currently limited [7, 8]. There is growing interest in finding ways to use genotyping in clinical practice for risk stratification and designing new therapeutic targets. Two points facilitate this endeavor. Firstly, cardiovascular disease typically results from the impact of multiple genetic and environmental components. Different combinations of SNPs, CNVs, mutations in specific genes, and environmental factors may result in similar clinical phenotypes. Second, the promise of personalizing the delivery of interventions. In this essay, we will focus on describing the attempts to identify linked genetic variations in genes associated with increased risk of cardiovascular disease and on providing a short review of the recent discoveries in the genetic background of key factors involved in atherogenesis. Furthermore, we acknowledge that the consensus in the clinical community at present is that while these measures are useful for research, clinical guidance based on genetic testing is not yet routinely feasible [9, 10].

HERITABILITY OF CARDIOVASCULAR DISEASE

Heritability refers to the proportion of phenotypic variance attributed to genetic factors. It varies depending on factors such as age, environment, and genetic background. Research shows that heritability is relatively high for cardiovascular disease traits like blood pressure and cholesterol. Traditional risk factors like obesity and diabetes also have high levels of heritability. However, the complexity of the trait can lower its heritability when calculated for actual diseases. Nonetheless, twin-based data indicate a heritability of 30-70% for most cardiovascular disease endophenotypes [11, 12]. It is also worth noting that for the majority of CVD endophenotypes, a significant genetic association explaining them is still not determined. Major breakthroughs and large undertakings with increasingly large sample sizes are helping to identify associations. To date, however, most of the identified associations contribute only a small effect to the large variance seen in cardiovascular phenotypes, which cannot be explained by established risk factors. A more compound or polygenic model, with influences from a variety of rare and common genetic variants alongside environmental determinants, is seen as a likely cause of the genetic predisposition to CVD [13, 14].

GENETIC TESTING AND SCREENING FOR CARDIOVASCULAR DISEASE

Genetic testing for individuals and their relatives can be a powerful tool in the diagnosis, stratification, and treatment of cardiovascular disease. Genetic testing can definitively identify genetic contributions that lead to disease, allowing healthcare professionals to tailor the most appropriate clinical route available. This can include lifestyle advice, preventative therapies, monitoring, and targeted therapies. Given the complex nature of genetic testing, it is essential for genetic services to be offered by professionals with the correct skills and knowledge of the pitfalls and complexities, and with a good understanding of the specific genetic and ethical issues pertaining to genetics and clinical cardiology. With the large proportions of cardiovascular disease that are made up of atrial fibrillation, hypertension, stroke, and heart attacks, it is also incredibly important to look forward to the preventative use of genetic tests. This raises discussion around predictive genetic testing, which is based on the ability to identify whether people have an increased genetic risk of developing disease, even if they possess no symptoms at the time of testing. Such actions conspire between an early age, asymptomatic, and at-risk phenotype. Preventative measures can be taken to reduce the chances of the onset and management, including lifestyle and medication-based factors [15, 16].

CURRENT RESEARCH AND FUTURE DIRECTIONS

Despite the tremendous progress that has been made in the field of human and cardiovascular genetics, our understanding of the genetic basis of all types of cardiovascular disease is still in its infancy. Because of the considerable complexity and heterogeneity of cardiovascular disease, it is unlikely that any single study will uncover the complete genetic underpinning of these diseases. Technological progress, fueled by international consortiums that are characterizing the human genome sequence, high-throughput SNP genotyping systems, and new DNA sequencing strategies, as well as epidemiologic development of large and diverse study populations, may allow the quest to move forward more rapidly and effectively.

Nevertheless, the undertaking of significant size and scope will continue to be necessary, and we will increasingly rely on studies involving the ongoing collection and storage of DNA. It will also be necessary to expand our genetic focus to include larger and more diverse cohorts. Virtually all of the progress in human genetics has been derived from the study of European-derived populations; little is known about the genomic and genetic basis of common and rare genetic variation in non-European populations. Given the significant genetic differences among humans, the current exclusion of non-European populations from genetic studies limits progress toward an understanding of the genetic basis of disease in diverse human populations. The nature of these differences can be seen from regional disparities in patterns of genetic variation, linkage disequilibrium and haplotype structure, and allele frequencies; our ability to detect associations for unknown novel genetic variants will probably be severely hampered. Social factors are partially responsible for the lack of studies in these groups, but such studies depend on the design of genetic epidemiologic studies that take full advantage of population heterogeneity and the linkage to genetic resources [15, 17].

CONCLUSION

Genetics plays a crucial role in the development of cardiovascular disease, with heritability estimates ranging from 30-70% for various CVD-related traits. Despite the identification of multiple genetic factors, the clinical application of these findings is still evolving. Advances in genotyping technologies and large-scale genomic studies will likely enhance our ability to predict cardiovascular risk and personalize treatment approaches. The inclusion of non-European populations in research is essential to fully capture the global genetic diversity of CVD. Continued exploration of genetic factors will pave the way for more precise, individualized interventions in the prevention and treatment of cardiovascular disease.

REFERENCES

1. Birger M, Kaldjian AS, Roth GA, Moran AE, Dieleman JL, Bellows BK. Spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996 to 2016. Circulation. 2021 Jul 27;144(4):271-82. ahajournals.org
2. Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, Gale CP, Achenbach S, Weidinger F, Vardas P. Epidemiology of cardiovascular disease in Europe. Nature Reviews Cardiology. 2022 Feb;19(2):133-43. unibocconi.it
3. Kumar JP, Sadique M, Shah SR. Mathematical study of blood flow through blood vessels under diseased condition. International Journal of Multidisciplinary Research and Development. 2022;9(6):31-44. researchgate.net
4. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020 Feb;75(2):285-92.
5. Damaskos C, Garmpis N, Kollia P, Mitsiopoulos G, Barlampa D, Drosos A, Patsouras A, Gravvanis N, Antoniou V, Litos A, Diamantis E. Assessing cardiovascular risk in patients with diabetes: an update. Current cardiology reviews. 2020 Nov 1;16(4):266-74. nih.gov
6. Trimarco V, Izzo R, Morisco C, Mone P, Virginia Manzi M, Falco A, Pacella D, Gallo P, Lembo M, Santulli G, Trimarco B. High HDL (high-density lipoprotein) cholesterol increases cardiovascular risk in hypertensive patients. Hypertension. 2022 Oct;79(10):2355-63. ahajournals.org
7. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein (a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and vascular biology. 2022 Jan;42(1):e48-60. ahajournals.org
8. Bays HE, Taub PR, Epstein E, Michos ED, Ferraro RA, Bailey AL, Kelli HM, Ferdinand KC, Echols MR, Weintraub H, Bostrom J. Ten things to know about ten cardiovascular disease risk factors. American journal of preventive cardiology. 2021 Mar 1;5:100149.
9. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular disease: lessons learned from air pollution. Nature Reviews Cardiology. 2020 Oct;17(10):656-72. nih.gov
10. Aragam KG, Natarajan P. Polygenic scores to assess atherosclerotic cardiovascular disease risk: clinical perspectives and basic implications. Circulation research. 2020 Apr 24;126(9):1159-77.
11. Tomaselli GF, Roy-Puckelwartz MJ. Early-Onset Atrial Fibrillation and Heritable Heart Disease—To Test or Not to Test?. JAMA cardiology. 2021 Dec 1;6(12):1359-61.

12. Aung N, Young WJ, Van Duijvenboden S, Ramírez J, Petersen SE, Munroe PB. Genetic Architecture of Quantitative Cardiovascular Traits: Blood Pressure, ECG and Imaging Phenotypes. In2020 Computing in Cardiology 2020 Sep 13 (pp. 1-4). IEEE. qmul.ac.uk
13. Bai W, Suzuki H, Huang J, Francis C, Wang S, Tarroni G, Guitton F, Aung N, Fung K, Petersen SE, Piechnik SK. A population-based phenome-wide association study of cardiac and aortic structure and function. Nature medicine. 2020 Oct;26(10):1654-62. nih.gov
14. Lu Y, Wang Z, Georgakis MK, Lin H, Zheng L. Genetic liability to depression and risk of coronary artery disease, myocardial infarction, and other cardiovascular outcomes. Journal of the American Heart Association. 2021 Jan 5;10(1):e017986. ahajournals.org
15. Morton SU, Quiat D, Seidman JG, Seidman CE. Genomic frontiers in congenital heart disease. Nature Reviews Cardiology. 2022 Jan;19(1):26-42. nih.gov
16. Zhou Z, Lin Y, Zhou Z, Lin Y, Zhou Z, Lin Y, Zhou Z, Lin Y, Zhou Z, Lin Y. Cardiovascular disease. InClinical Molecular Diagnostics 2021 Jul 9 (pp. 583-594). Singapore: Springer Singapore.
17. Suluba E, Shuwei L, Xia Q, Mwanga A. Congenital heart diseases: genetics, non-inherited risk factors, and signaling pathways. Egyptian Journal of Medical Human Genetics. 2020 Dec;21:1-2. springer.com

CITE AS: Katu Amina H. (2024). The role of Genetics in Cardiovascular Disease. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2):45-48. https://doi.org/10.59298/RIJPP/2024/3234548